Changes in Circulating Lysyl Oxidase-Like-2 (LOXL2) Levels, HOMA, and Fibrosis after Sustained Virological Response by Direct Antiviral Therapy.

Angela PuenteJose Ignacio ForteaMiguel PosadasAgustin Garcia BlancoLaura RasinesJoaquin CabezasMaria Teresa Arias LosteSusana LlerenaPaula IruzubietaEmilio FábregaJavier Crespo

Published in: Journal of clinical medicine (2019)

Regression of LSM was reached in 82% of patients. Downregulated LOXL2 was demonstrated post-SVR, with overexpression in cirrhotic patients being a potential therapy goal in selected patients.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
peritoneal dialysis
prognostic factors
stem cells
patient reported outcomes
bone marrow
climate change
antiretroviral therapy
hiv infected patients